M Ognjanovic
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
M Ognjanovic has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Aj Harris
Key Laboratory of Plant Resources Conservation and Sustainable Utilization, South China Botanical Garden Chinese Academy of Sciences Guangzhou China
1 shared publication - Arthur Ingersen
Department of Biomedical Sciences, Faculty of Health and Medical Sciences University of Copenhagen Copenhagen Denmark
1 shared publication B Marjanović
Institute of Mother and Child Health of Serbia, Belgrade, Yugoslavia
1 shared publication- Ben Christopher Reynolds
Paediatric Renal Unit, Royal Hospital for Children, Glasgow, UK
1 shared publication - Casper Soendenbroe
Institute of Sports Medicine Copenhagen, Department of Orthopaedic Surgery, Copenhagen University Hospital - Bispebjerg and Frederiksberg, Copenhagen, Denmark
1 shared publication - Charlotte Suetta
Department of Clinical Medicine, Faculty of Health, University of Copenhagen , Blegdamsvej 3b, 2200 Copenhagen
1 shared publication
Latest Publications
- Open Access
- 25 May 2023
- Published by Rockefeller University Press in Journal of General Physiology
- Vol. 155 (7)
Physical activity impacts resting skeletal muscle myosin conformation and lowers its ATP consumption
It has recently been established that myosin, the molecular motor protein, is able to exist in two conformations in relaxed skeletal muscle. These conformations are known as the super-relaxed (SRX) and disordered-relaxed (DRX) states and are finely balanced to optimize ATP consumption and skeletal muscle metabolism. Indeed, SRX myosins are thought to have a 5- to 10-fold reduction in ATP turnover compared with DRX myosins. Here, we investigated whether chronic physical activity in humans would be associated with changes in the proportions of SRX and DRX skeletal myosins. For that, we isolated muscle fibers from young men of various physical activity levels (sedentary, moderately physically active, endurance-trained, and strength-trained athletes) and ran a loaded Mant-ATP chase protocol. We observed that in moderately physically active individuals, the amount of myosin molecules in the SRX state in type II muscle fibers was significantly greater than in age-matched sedentary individuals. In parallel, we did not find any difference in the proportions of SRX and DRX myosins in myofibers between highly endurance- and strength-trained athletes. We did however observe changes in their ATP turnover time. Altogether, these results indicate that physical activity level and training type can influence the resting skeletal muscle myosin dynamics. Our findings also emphasize that environmental stimuli such as exercise have the potential to rewire the molecular metabolism of human skeletal muscle through myosin.
- 25 May 2023
- Published by Rockefeller University Press in Journal of General Physiology
- Vol. 155 (7)
Open AccessPhysical activity impacts resting skeletal muscle myosin conformation and lowers its ATP consumption
It has recently been established that myosin, the molecular motor protein, is able to exist in two conformations in relaxed skeletal muscle. These conformations are known as the super-relaxed (SRX) and disordered-relaxed (DRX) states and are finely balanced to optimize ATP consumption and skeletal muscle metabolism. Indeed, SRX myosins are thought to have a 5- to 10-fold reduction in ATP turnover compared with DRX myosins. Here, we investigated whether chronic physical activity in humans would be associated with changes in the proportions of SRX and DRX skeletal myosins. For that, we isolated muscle fibers from young men of various physical activity levels (sedentary, moderately physically active, endurance-trained, and strength-trained athletes) and ran a loaded Mant-ATP chase protocol. We observed that in moderately physically active individuals, the amount of myosin molecules in the SRX state in type II muscle fibers was significantly greater than in age-matched sedentary individuals. In parallel, we did not find any difference in the proportions of SRX and DRX myosins in myofibers between highly endurance- and strength-trained athletes. We did however observe changes in their ATP turnover time. Altogether, these results indicate that physical activity level and training type can influence the resting skeletal muscle myosin dynamics. Our findings also emphasize that environmental stimuli such as exercise have the potential to rewire the molecular metabolism of human skeletal muscle through myosin.
- 27 April 2016
- Published by BMJ in Archives of Disease in Childhood
- Vol. 101 (Suppl 1) , A224-A225
G386 Surveillance biopsies of tacrolimus effect in childhood nephrotic syndrome
Objectives Tacrolimus is increasingly advocated as a steroid sparing agent in the management of nephrotic syndrome. As concerns exist about long term nephrotoxicity, interval renal biopsies have been advocated to detect early changes. Associations between histological changes and patient factors are not well established. Methods Single centre review of surveillance renal histology of children who received tacrolimus to treat nephrotic syndrome between 2002–2015. Duration on tacrolimus and nephrotoxicity. Average trough 12 hours tacrolimus levels from starting tacrolimus to first biopsy. Toxicity associated with higher levels: 0/10 showed toxicity with levels of 4.36 to 5.54 μg/L vs. 9/15 (60%) with levels 5.69 to 7.36 μ/L (p < 0.0001) Results 25 children (16 male, 1 non-caucasian, 21 minimal change, 4 FSGS) commenced tacrolimus at median age 4.0 years (range 1.4–8.9). 9/25(35%) of first biopsy taken after median duration 4.7 years (range 1.9 to 6.9) demonstrated features of calcineurin inhibitor (CNI) nephrotoxicity. Toxicity was associated with higher mean 12-hour trough serum tacrolimus levels: 0/11 showed toxicity with levels of 4.36 to 5.54 µg/L vs. 9/15 (60%) with levels 5.69 to 7.36 µg/L (p < 0.0001). No association was found with number of relapses, gender or duration of time on tacrolimus. Eight patients without initial CNI toxicity underwent second biopsy at a median time of 4.9 (range, 4.0–5.4) years later. Two developed toxicity. Estimated glomerular filtration rate in those who developed toxicity was normal. We attempted tacrolimus weaning in 20 patients: 11 patients relapsed, 4 within 2 months, further 5 within 1 year after dose reduction (See Figures 1 and 2). Conclusion Significant number of children on tacrolimus showed histological nephrotoxicity after a short duration of therapy. In this small single centre experience, toxicity correlated with tacrolimus level rather than duration. A high number relapsed shortly following dose reduction. We suggest maintaining tacrolimus levels ≤5.5 µg/L to minimise nephrotoxicity.
- 27 April 2016
- Published by BMJ in Archives of Disease in Childhood
- Vol. 101 (Suppl 1) , A224-A225
G386 Surveillance biopsies of tacrolimus effect in childhood nephrotic syndrome
Objectives Tacrolimus is increasingly advocated as a steroid sparing agent in the management of nephrotic syndrome. As concerns exist about long term nephrotoxicity, interval renal biopsies have been advocated to detect early changes. Associations between histological changes and patient factors are not well established. Methods Single centre review of surveillance renal histology of children who received tacrolimus to treat nephrotic syndrome between 2002–2015. Duration on tacrolimus and nephrotoxicity. Average trough 12 hours tacrolimus levels from starting tacrolimus to first biopsy. Toxicity associated with higher levels: 0/10 showed toxicity with levels of 4.36 to 5.54 μg/L vs. 9/15 (60%) with levels 5.69 to 7.36 μ/L (p < 0.0001) Results 25 children (16 male, 1 non-caucasian, 21 minimal change, 4 FSGS) commenced tacrolimus at median age 4.0 years (range 1.4–8.9). 9/25(35%) of first biopsy taken after median duration 4.7 years (range 1.9 to 6.9) demonstrated features of calcineurin inhibitor (CNI) nephrotoxicity. Toxicity was associated with higher mean 12-hour trough serum tacrolimus levels: 0/11 showed toxicity with levels of 4.36 to 5.54 µg/L vs. 9/15 (60%) with levels 5.69 to 7.36 µg/L (p < 0.0001). No association was found with number of relapses, gender or duration of time on tacrolimus. Eight patients without initial CNI toxicity underwent second biopsy at a median time of 4.9 (range, 4.0–5.4) years later. Two developed toxicity. Estimated glomerular filtration rate in those who developed toxicity was normal. We attempted tacrolimus weaning in 20 patients: 11 patients relapsed, 4 within 2 months, further 5 within 1 year after dose reduction (See Figures 1 and 2). Conclusion Significant number of children on tacrolimus showed histological nephrotoxicity after a short duration of therapy. In this small single centre experience, toxicity correlated with tacrolimus level rather than duration. A high number relapsed shortly following dose reduction. We suggest maintaining tacrolimus levels ≤5.5 µg/L to minimise nephrotoxicity.
- 1 July 1996
- Published by Wiley in Acta Paediatrica
- Vol. 85 (7) , 882-883
Shunt nephritis associated with Moraxella bovis
Moraxella bovis was repeatedly isolated from cerebrospinal fluid in a girl with two episodes of shunt nephritis. Clinical remission of nephritis was achieved only after shunt replacement. A list of about 20 infectious agents reported to date in patients with shunt nephritis is given. M. bovis is yet another agent previously not reported in patients with shunt nephritis.
- 1 July 1996
- Published by Wiley in Acta Paediatrica
- Vol. 85 (7) , 882-883
Shunt nephritis associated with Moraxella bovis
Moraxella bovis was repeatedly isolated from cerebrospinal fluid in a girl with two episodes of shunt nephritis. Clinical remission of nephritis was achieved only after shunt replacement. A list of about 20 infectious agents reported to date in patients with shunt nephritis is given. M. bovis is yet another agent previously not reported in patients with shunt nephritis.